Keywords: Life Sciences Entrepreneurs, Antiplatlet, NmC, Ambit BioSciences, Quizartinib, AML, Leumkemia
Financing for Life Sciences Entrepreneurs antiplatelet candidate NmC; and Ambit's AML drug
Article | 06 November 2012
Life Science Entrepreneurs, a Spanish company dedicated to the early-stage development of high-risk/very high return ventures, has announced the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
